Filana Therapeutics
FLNA
26 hedge funds and large institutions have $16.1M invested in Filana Therapeutics in 2018 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 4 closing their positions.
73% more capital invested
Capital invested by funds: $9.31M → $16.1M (+$6.79M)
0% more funds holding
Funds holding: 26 → 26 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
2.34% less ownership
Funds ownership: 35.26% → 32.92% (-2.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$2.02M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$156K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$137K |
| 4 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
+$92.5K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$76.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$1.3M |
| 2 |
Renaissance Technologies
New York
|
-$245K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$84.9K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$79K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$77.2K |
FLNA Hedge Fund Activity: Q1 2018 in Review
26 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Filana Therapeutics (FLNA) for Q1 2018, worth a combined $16.1M — up 73% from $9.31M a quarter earlier.
Fund positioning in FLNA was balanced in Q1 2018: 4 funds opened new positions, 4 closed out, 7 added to existing stakes and 7 trimmed.
The largest buyer was Nantahala Capital Management, adding an estimated $2.02M. The largest seller was BVF Inc, exiting entirely with an estimated $1.3M sold.
- 26 institutional investors held Filana Therapeutics (FLNA) as of Q1 2018, unchanged from Q4 2017.
- Funds reported $16.1M of Filana Therapeutics stock for Q1 2018, up 73% quarter-over-quarter.
- 4 funds opened new Filana Therapeutics positions in Q1 2018 and 4 closed out, a net change of 0 holders.
- The largest Filana Therapeutics buyer in Q1 2018 was Nantahala Capital Management, an estimated $2.02M added.
- The largest Filana Therapeutics seller in Q1 2018 was BVF Inc, an estimated $1.3M sold.
Based on aggregated 13F filings for Q1 2018.